For successful vector-based gene therapy manufacturing, the selected adeno-associated virus (AAV) vector production system must produce vector at sufficient scale. However, concerns have arisen regarding the quality of vector produced using different systems. In this study, we compared AAV serotypes 1, 8, and 9 produced by two different systems (Sf9/baculovirus and HEK293/transfection) and purified by two separate processes. We evaluated capsid properties, including protein composition, post-translational modification, particle content profiles, and in vitro and in vivo vector potency. Vectors produced in the Sf9/baculovirus system displayed reduced incorporation of viral protein 1 and 2 into the capsid, increased capsid protein deamidation, increased empty and partially packaged particles in vector preparations, and an overall reduced potency. The differences observed were largely independent of the harvest method and purification process. These findings illustrate the need for careful consideration when choosing an AAV vector production system for clinical production.
Get full access to this article
View all access options for this article.
References
1.
ClementN, GriegerJC. Manufacturing of recombinant adeno-associated viral vectors for clinical trials. Mol Ther Methods Clin Dev, 2016; 3:16002.
2.
LockM, AlviraM, VandenbergheLH, et al.Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Human Gene Ther, 2010; 21:1259–1271.
3.
WrightJF, WellmanJ, HighKA. Manufacturing and regulatory strategies for clinical AAV2-hRPE65. Curr Gene Ther, 2010; 10:341–349.
4.
PowersAD, PirasBA, ClarkRK, et al.Development and optimization of AAV hFIX particles by transient transfection in an iCELLis((R)) fixed-bed bioreactor. Hum Gene Ther Methods, 2016; 27:112–121.
5.
UrabeM, DingC, KotinRM. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther, 2002; 13:1935–1943.
6.
ViragT, CecchiniS, KotinRM. Producing recombinant adeno-associated virus in foster cells: Overcoming production limitations using a baculovirus-insect cell expression strategy. Hum Gene Ther, 2009; 20:807–817.
7.
SmithRH, LevyJR, KotinRM. A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells. Mol Ther, 2009; 17:1888–1896.
8.
KohlbrennerE, AslanidiG, NashK, et al.Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system. Mol Ther, 2005; 12:1217–1225.
9.
ChenH. Intron splicing-mediated expression of AAV Rep and Cap genes and production of AAV vectors in insect cells. Mol Ther, 2008; 16:924–930.
10.
MietzschM, CasteleynV, WegerS, et al.OneBac 2.0: Sf9 cell lines for production of AAV5 vectors with enhanced infectivity and minimal encapsidation of foreign DNA. Hum Gene Ther, 2015; 26:688–697.
11.
MietzschM, GrasseS, ZurawskiC, et al.OneBac: Platform for scalable and high-titer production of adeno-associated virus serotype 1–12 vectors for gene therapy. Hum Gene Ther, 2014; 25:212–222.
12.
KondratovO, MarsicD, CrossonSM, et al.Direct head-to-head evaluation of recombinant adeno-associated viral vectors manufactured in human versus insect cells. Mol Ther, 2017; 25:2661–2675.
13.
RumachikNG, MalakerSA, PoweleitN, et al.Methods matter: Standard production platforms for recombinant AAV produce chemically and functionally distinct vectors. Mol Ther Methods Clin Dev, 2020; 18:98–118.
14.
GalibertL, SavyA, DickxY, et al.Origins of truncated supplementary capsid proteins in rAAV8 vectors produced with the baculovirus system. PLoS One, 2018; 13:e0207414.
15.
GilesAR, SimsJJ, TurnerKB, et al.Deamidation of amino acids on the surface of adeno-associated virus capsids leads to charge heterogeneity and altered vector function. Mol Ther, 2018; 26:2848–2862.
16.
DavidoffAM, NgCY, ZhouJ, et al.Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. Blood, 2003; 102:480–488.
17.
HanSO, RonzittiG, ArnsonB, et al.Low-dose liver-targeted gene therapy for pompe disease enhances therapeutic efficacy of ERT via immune tolerance induction. Mol Ther Methods Clin Dev, 2017; 4:126–136.
18.
PanedaA, VanrellL, MauleonI, et al.Effect of adeno-associated virus serotype and genomic structure on liver transduction and biodistribution in mice of both genders. Hum Gene Ther, 2009; 20:908–917.
19.
PiechnikM, AmendumPC, SawamotoK, et al.Sex difference leads to differential gene expression patterns and therapeutic efficacy in mucopolysaccharidosis IVA murine model receiving AAV8 gene therapy. Int J Mol Sci, 2022; 23:12693.
20.
LockM, McGorrayS, AuricchioA, et al.Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material. Hum Gene Ther, 2010; 21:1273–1285.
21.
AkacheB, GrimmD, ShenX, et al.A two-hybrid screen identifies cathepsins B and L as uncoating factors for adeno-associated virus 2 and 8. Mol Ther, 2007; 15:330–339.
22.
AyusoE, BlouinV, LockM, et al.Manufacturing and characterization of a recombinant adeno-associated virus type 8 reference standard material. Hum Gene Ther, 2014; 25:977–987.
23.
EllisBL, HirschML, BarkerJC, et al.A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with nine natural adeno-associated virus (AAV1–9) and one engineered adeno-associated virus serotype. Virol J, 2013; 10:74.
24.
van ReeR. Carbohydrate epitopes and their relevance for the diagnosis and treatment of allergic diseases. Int Arch Allergy Immunol, 2002; 129:189–197.
25.
WrightJF. Product-related impurities in clinical-grade recombinant AAV vectors: Characterization and risk assessment. Biomedicines, 2014; 2:80–97.
26.
Food & Drug Administration. Human Gene Therapy for Neurodegenerative Diseases. Center for Biologics Evaluation and Research; 2021. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-neurodegenerative-diseases [Last accessed: August1, 2023]
27.
BecerraSP, KoczotF, FabischP, et al.Synthesis of adeno-associated virus structural proteins requires both alternative mRNA splicing and alternative initiations from a single transcript. J Virol, 1988; 62:2745–2754.
28.
GirodA, WobusCE, ZadoriZ, et al.The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol, 2002; 83:973–978.
29.
GriegerJC, JohnsonJS, Gurda-WhitakerB, et al.Surface-exposed adeno-associated virus Vp1-NLS capsid fusion protein rescues infectivity of noninfectious wild-type Vp2/Vp3 and Vp3-only capsids but not that of fivefold pore mutant virions. J Virol, 2007; 81:7833–7843.
30.
JohnsonFB, OzerHL, HogganMD. Structural proteins of adenovirus-associated virus type 3. J Virol, 1971; 8:860–863.
31.
WuP, XiaoW, ConlonT, et al.Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol, 2000; 74:8635–8647.
32.
MietzschM, HeringH, HammerEM, et al.OneBac 2.0: Sf9 cell lines for production of AAV1, AAV2, and AAV8 vectors with minimal encapsidation of foreign DNA. Hum Gene Ther Methods, 2017; 28:15–22.
33.
VandenbergheLH, XiaoR, LockM, et al.Efficient serotype-dependent release of functional vector into the culture medium during adeno-associated virus manufacturing. Hum Gene Ther, 2010; 21:1251–1257.
34.
WuZ, YangH, ColosiP. Effect of genome size on AAV vector packaging. Mol Ther, 2010; 18:80–86.
35.
KapranovP, ChenL, DederichD, et al.Native molecular state of adeno-associated viral vectors revealed by single-molecule sequencing. Hum Gene Ther, 2012; 23:46–55.
36.
KingJA, DubielzigR, GrimmD, et al.DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids. EMBO J, 2001; 20:3282–3291.
37.
GaoK, LiM, ZhongL, et al.Empty virions in AAV8 vector preparations reduce transduction efficiency and may cause total viral particle dose-limiting side effects. Mol Ther Methods Clin Dev, 2014; 1:20139.
38.
UrabeM, XinK-Q, ObaraY, et al.Removal of empty capsids from type 1 adeno-associated virus vector stocks by anion-exchange chromatography potentiates transgene expression. Mol Ther, 2006; 13:823–828.
39.
WrightJF. AAV empty capsids: For better or for worse?. Mol Ther, 2014; 22:1–2.
40.
LopezMF, BerggrenK, ChernokalskayaE, et al.A comparison of silver stain and SYPRO Ruby Protein Gel Stain with respect to protein detection in two-dimensional gels and identification by peptide mass profiling. Electrophoresis, 2000; 21:3673–3683.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
